Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers
Authors: Gian Luca Salvagno, Brandon M. Henry, Laura Pighi, Simone De Nitto, Gian Luca Gianfilippi, Giuseppe Lippi
Journal: Journal of Infection (2021)

We read with interest the article by Tré-Hardy et al.,1Tré-Hardy M. Cupaiolo R. Wilmet A. Beukinga I. Blairon L. Waning antibodies in SARS-CoV-2 naïve vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.J Infect. 2021; (Jun 20:S0163-4453(21)00314-5Epub ahead of print)https://doi.org/10.1016/j.jinf.2021.06.017Abstract Full Text Full Text PDF Scopus (25) Google Scholar who monitored the anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike antibodies levels using the LIAISON® SARS-CoV-2 IgG kit in naïve recipients of mRNA-1273 vaccine. Although it was found that these antibodies persisted up to 3 months after vaccination, a significant decrease of their serum levels could be observed in some seronegative participants, thus supporting the opportunity to administer an additional vaccine dose in specific subgroups of recipients. To provide further elements on this important public health matter, we report here an ad-interim analysis of data obtained after a 3-month follow-up in a cohort of healthcare workers who received the Pfizer BNT162b2 mRNA vaccine. The study population consisted of healthcare workers undergoing voluntary vaccination with Pfizer BNT162b2 mRNA COVID-19 vaccine (Comirnaty; Pfizer Inc, NY, USA) at the hospital of Peschiera del Garda (Italy). All subjects received two 30 μg BNT162b2 vaccine doses, 3 weeks apart. Blood was collected immediately before receiving the first vaccine dose, immediately before receiving the second vaccine dose (i.e., 21 days after the first dose), as well as 50 days and 3 months after the first vaccine dose, via a previously specified protocol.2Salvagno G.L. Henry B.M. di Piazza G. Pighi L. De Nitto S. Bragantini D. et al.Anti-SARS-CoV-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mRNA BNT162b2 vaccination.Diagn (Basel). 2021; 11: 11832Google Scholar Serum was separated by centrifugation for 15 min at 1500 × g at room temperature, divided in aliquots and stored at −70 °C until measurement. Total anti-SARS-CoV-2 antibodies were assayed using the Roche Elecsys Anti-SARS-CoV-2 S chemiluminescent immunoassay, on a Roche Cobas 6000 (Roche Diagnostics, Basel, Switzerland). This method was found to have good correlation and agreement with a pseudovirus neutralizing test (r = 0.58; Cohen's kappa, 0.60)3Eberhardt K.A. Dewald F. Heger E. Gieselmann L. Vanshylla K. Wirtz M. et al.Evaluation of a new spike (S)-protein-based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG.Microorganisms. 2021; 9: 733Crossref PubMed Scopus (20) Google Scholar. The statistical analysis was conducted using Analyse-it (Analyse-it Software Ltd, Leeds, UK), with results of measurements expressed as median and interquartile range (IQR). Comparisons between groups were carried out with Mann-Whitney test or Chi square test (with Yates' correction), when appropriate. All participants provided written informed consents for receiving BNT162b2 mRNA COVID-19 vaccination and undergoing total anti-SARS-CoV-2 antibodies follow-up. The study was conducted in accordance with the Declaration of Helsinki and cleared by the Ethics Committee of Verona and Rovigo Provinces (3246CESC). The final study population consisted of 871 healthcare workers (median age 45 years, IQR 34–53 years; 65.7% females), 192 (22.0%) of which had positive total anti-SARS-CoV-2 S at baseline (i.e., >0.8 kU/L). No significant differences in age (p = 0.191) or sex (p = 0.101) were observed between baseline seronegative and seropositive subjects. The kinetics of total anti-SARS-CoV-2 S antibodies is shown in Fig. 1. The antibodies levels were consistently higher in baseline total anti-SARS-CoV-2 antibodies seropositive subjects throughout the study period (i.e., p < 0.001), and reached a peak after the second vaccine dose, though a significant decline was then observed in both cohorts at 3 months. Compared to the value measured at 30 days after the second vaccine dose, the decline was nearly 2-fold more accentuated in the seropositive than in the seronegative cohort (i.e., −57% vs. −33%; p < 0.001). Although no subject in either cohort displayed total anti-SARS-CoV-2 S antibodies values below the method-dependant cut-off (i.e., 0.8 kU/L), a reduction in serum levels was observed in 568/679 (83.7%) baseline seronegative subjects and in 173/192 (90.1%) baseline seropositive subjects (p = 0.018). Interestingly, in baseline anti-SARS-CoV-2 seronegative subjects, the total anti-SARS-CoV-2 S antibodies values were significantly lower (i.e., p<0.001) at 30 days and at 3 months after the first vaccine dose in those aged >65 years compared to younger patients (Fig. 1). No statistically significant differences were instead observed between sexes in total anti-SARS-CoV-2 S antibodies levels as well as in the 3-month variation. In conclusion, the results of our study extend the evidence provided by Tré-Hardy et al.1Tré-Hardy M. Cupaiolo R. Wilmet A. Beukinga I. Blairon L. Waning antibodies in SARS-CoV-2 naïve vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.J Infect. 2021; (Jun 20:S0163-4453(21)00314-5Epub ahead of print)https://doi.org/10.1016/j.jinf.2021.06.017Abstract Full Text Full Text PDF Scopus (25) Google Scholar that total anti-SARS-CoV-2 S antibodies levels tend to decline at 3 months after the first vaccine dose, though we also showed that such decline occurs in both baseline seropositive and seronegative subjects, and with serum levels that tend to be significantly lower in older subjects. These findings not only confirm the importance of serological testing for monitoring the immunogenic response after vaccination,4Lippi G. Henry B.M. Plebani M. Anti-SARS-CoV-2 antibodies testing in recipients of COVID-19 vaccination: why, when, and how?.Diagn (Basel). 2021; 11: 941Crossref PubMed Scopus (46) Google Scholar but provide further support to the conclusion that personalization of COVID-19 vaccine administration, with use of further vaccine boosters, may be advisable in selected categories of the population. The study protocol (number 3246CESC) was cleared by the Ethics Committee of the Provinces of Verona and Rovigo. All subjects were informed of the study and voluntarily agreed to participate, providing a written consent). None declared.